Matching articles for "Protease inhibitors"
Ibalizumab-uiyk (Trogarzo) for Multidrug-Resistant HIV
The Medical Letter on Drugs and Therapeutics • April 23, 2018; (Issue 1545)
The FDA has approved ibalizumab-uiyk (Trogarzo –
Theratechnologies/TaiMed), a CD4-directed monoclonal
antibody, for IV treatment of multidrug-resistant
HIV-1 (MDR-HIV) infection in...
The FDA has approved ibalizumab-uiyk (Trogarzo –
Theratechnologies/TaiMed), a CD4-directed monoclonal
antibody, for IV treatment of multidrug-resistant
HIV-1 (MDR-HIV) infection in heavily
antiretroviral-experienced adults with treatment
failure on their current regimen. Ibalizumab-uiyk is
the first biologic drug to be approved by the FDA for
treatment of HIV-1 infection.
Mavyret and Vosevi - Two New Combinations for Chronic HCV Infection
The Medical Letter on Drugs and Therapeutics • October 9, 2017; (Issue 1531)
The FDA has approved Mavyret (Abbvie) and Vosevi
(Gilead), two new fixed-dose combinations of direct-acting
antiviral (DAA) drugs, for treatment of chronic
hepatitis C virus (HCV) infection caused by any of...
The FDA has approved Mavyret (Abbvie) and Vosevi
(Gilead), two new fixed-dose combinations of direct-acting
antiviral (DAA) drugs, for treatment of chronic
hepatitis C virus (HCV) infection caused by any of the
six major HCV genotypes in patients without cirrhosis
or with compensated cirrhosis. Both are approved for
use in treatment-experienced patients. Mavyret is also
approved for treatment-naive patients.
Odefsey - Another NNRTI Combination for HIV
The Medical Letter on Drugs and Therapeutics • May 9, 2016; (Issue 1494)
The FDA has approved Odefsey (Gilead), a once-daily,
fixed-dose combination of the non-nucleoside
reverse transcriptase inhibitor (NNRTI) rilpivirine
and the nucleoside/nucleotide reverse...
The FDA has approved Odefsey (Gilead), a once-daily,
fixed-dose combination of the non-nucleoside
reverse transcriptase inhibitor (NNRTI) rilpivirine
and the nucleoside/nucleotide reverse transcriptase
inhibitors (NRTIs) emtricitabine and tenofovir
alafenamide, for initial treatment of HIV-1 infection in
patients with HIV-1 RNA (viral load) ≤100,000 copies/mL or to replace a stable antiretroviral regimen in
patients who have been virologically suppressed
(viral load <50 copies/mL) for at least six months with
no history of treatment failure.
Elvitegravir (Vitekta) for HIV
The Medical Letter on Drugs and Therapeutics • January 18, 2016; (Issue 1486)
The FDA has approved elvitegravir (Vitekta – Gilead),
an integrase strand transfer inhibitor (INSTI), for use
with a protease inhibitor (PI) plus ritonavir and other
antiretroviral drugs for treatment of...
The FDA has approved elvitegravir (Vitekta – Gilead),
an integrase strand transfer inhibitor (INSTI), for use
with a protease inhibitor (PI) plus ritonavir and other
antiretroviral drugs for treatment of HIV-1 infection
in treatment-experienced adults. Elvitegravir is also
available in a fixed-dose combination (Stribild) with
the pharmacokinetic enhancer cobicistat and the
nucleoside/nucleotide reverse transcriptase inhibitors
(NRTIs) emtricitabine and tenofovir disoproxil
fumarate (DF). A similar combination (Genvoya) that
includes tenofovir alafenamide instead of tenofovir DF
was recently approved by the FDA and will be reviewed
in a future issue.
Triumeq: A 3-Drug Combination for HIV
The Medical Letter on Drugs and Therapeutics • January 5, 2015; (Issue 1459)
The FDA has approved Triumeq (Viiv Healthcare),
a fixed-dose combination of the integrase strand
transfer inhibitor (INSTI) dolutegravir and the
nucleoside reverse transcriptase inhibitors (NRTIs)
abacavir...
The FDA has approved Triumeq (Viiv Healthcare),
a fixed-dose combination of the integrase strand
transfer inhibitor (INSTI) dolutegravir and the
nucleoside reverse transcriptase inhibitors (NRTIs)
abacavir and lamivudine, for once-daily treatment of
HIV-1 infection. Dolutegravir (Tivicay) was approved
as a single agent in 2013.
A Combination of Ledipasvir and Sofosbuvir (Harvoni) for Hepatitis C
The Medical Letter on Drugs and Therapeutics • November 10, 2014; (Issue 1455)
The FDA has approved a fixed-dose combination (Harvoni [har voe' nee] – Gilead) of sofosbuvir and ledipasvir (led' i pas' vir), two oral direct-acting antiviral agents, for treatment of chronic hepatitis C...
The FDA has approved a fixed-dose combination (Harvoni [har voe' nee] – Gilead) of sofosbuvir and ledipasvir (led' i pas' vir), two oral direct-acting antiviral agents, for treatment of chronic hepatitis C virus (HCV) genotype 1 infection. Genotype 1 is responsible for 70-80% of HCV infections in the US. Sofosbuvir (Sovaldi) was approved earlier for use in combination with other antiviral drugs for treatment of HCV infection. Ledipasvir is a new drug.
Sofosbuvir (Sovaldi) for Chronic Hepatitis C
The Medical Letter on Drugs and Therapeutics • January 20, 2014; (Issue 1434)
The FDA has approved the nucleotide polymerase
inhibitor sofosbuvir (Sovaldi – Gilead) for use in
combination with other antiviral drugs for treatment of
chronic hepatitis C virus (HCV)...
The FDA has approved the nucleotide polymerase
inhibitor sofosbuvir (Sovaldi – Gilead) for use in
combination with other antiviral drugs for treatment of
chronic hepatitis C virus (HCV) infection.
Simeprevir (Olysio) for Chronic Hepatitis C
The Medical Letter on Drugs and Therapeutics • January 6, 2014; (Issue 1433)
The FDA has recently approved 2 new drugs for treatment of chronic hepatitis C virus (HCV) infection. Simeprevir (Olysio – Janssen) is the third oral protease inhibitor to be approved for use in combination...
The FDA has recently approved 2 new drugs for treatment of chronic hepatitis C virus (HCV) infection. Simeprevir (Olysio – Janssen) is the third oral protease inhibitor to be approved for use in combination with peginterferon and ribavirin for treatment of chronic HCV genotype 1 infection in adults with compensated liver disease. Telaprevir (Incivek) and boceprevir (Victrelis) were approved in 2011 for the same indication. Sofosbuvir (Sovaldi – Gilead), a nucleotide analog polymerase inhibitor that has been approved for use with and without interferon for treatment of multiple HCV genotypes, will be reviewed in the next issue of The Medical Letter.
Dolutegravir (Tivicay) for HIV
The Medical Letter on Drugs and Therapeutics • September 30, 2013; (Issue 1426)
The FDA has approved dolutegravir (doll-you-TEG-rah-veer;
Tivicay – Viiv Healthcare), an integrase strand
transfer inhibitor (INSTI), for treatment of HIV-1 infection
in adults and in children ≥12 years...
The FDA has approved dolutegravir (doll-you-TEG-rah-veer;
Tivicay – Viiv Healthcare), an integrase strand
transfer inhibitor (INSTI), for treatment of HIV-1 infection
in adults and in children ≥12 years old who weigh at least 40 kg. It is the third INSTI to be approved by the FDA; raltegravir
and elvitegravir were approved earlier.
Drugs for Tuberculosis
The Medical Letter on Drugs and Therapeutics • April 1, 2012; (Issue 116)
Tuberculosis (TB) is still a common cause of death
worldwide, and the prevalence of drug-resistant TB
poses challenges to its treatment and control.
Guidelines with detailed management recommendations
are...
Tuberculosis (TB) is still a common cause of death
worldwide, and the prevalence of drug-resistant TB
poses challenges to its treatment and control.
Guidelines with detailed management recommendations
are available from the American Thoracic
Society, Centers for Disease Control and Prevention
(CDC) and Infectious Diseases Society of America
(IDSA).
New Simvastatin Dosing Recommendations
The Medical Letter on Drugs and Therapeutics • August 8, 2011; (Issue 1370)
The FDA has announced changes in the labeling of simvastatin to reduce the risk of myopathy. These changes include limiting the use of the 80-mg maximum dose to patients who have been taking it for 12 months or...
The FDA has announced changes in the labeling of simvastatin to reduce the risk of myopathy. These changes include limiting the use of the 80-mg maximum dose to patients who have been taking it for 12 months or more without evidence of myopathy and new recommendations for use of simvastatin with other drugs. Simvastatin is available alone (Zocor, and others) and in combination with ezetimibe (Vytorin) and with niacin (Simcor).
Drugs for HIV Infection
The Medical Letter on Drugs and Therapeutics • June 1, 2011; (Issue 106)
Guidelines for use of antiretroviral agents continue to shift toward earlier and more continuous treatment, both to treat the patient and to prevent transmission of the disease to others. Resistance testing is...
Guidelines for use of antiretroviral agents continue to shift toward earlier and more continuous treatment, both to treat the patient and to prevent transmission of the disease to others. Resistance testing is now recommended when antiretroviral drugs are started. Increases in HIV RNA levels ("viral load") while on therapy may indicate development of drug resistance, requiring further testing and a change in the treatment regimen. Antiretroviral drugs interact with each other and with many other drugs; complete information on these interactions is available at www.aidsinfo.nih.gov.
Drugs for Tuberculosis
The Medical Letter on Drugs and Therapeutics • October 1, 2009; (Issue 86)
Even though the incidence continues to decline in the United States, tuberculosis (TB) is still a common cause of death worldwide, and the prevalence of drug-resistant TB poses severe challenges to its...
Even though the incidence continues to decline in the United States, tuberculosis (TB) is still a common cause of death worldwide, and the prevalence of drug-resistant TB poses severe challenges to its treatment and control. Guidelines with detailed management recommendations are available from the Centers for Disease Control and Prevention (CDC), American Thoracic Society and Infectious Diseases Society of America (IDSA).
Drugs for HIV Infection
The Medical Letter on Drugs and Therapeutics • February 1, 2009; (Issue 78)
New guidelines for use of antiretroviral agents have been published, with a shift towards earlier and more continuous treatment. HIV infection is treated with combinations of antiretroviral drugs depending on...
New guidelines for use of antiretroviral agents have been published, with a shift towards earlier and more continuous treatment. HIV infection is treated with combinations of antiretroviral drugs depending on the patientÆs HIV RNA levels ("viral load") and CD4 cell count. Increases in viral load while on therapy may indicate development of drug resistance, requiring further testing and a change in treatment regimen. Resistance testing is now recommended when a patient is first seen, regardless of when therapy will be started.
Etravirine (Intelence) for HIV Infection
The Medical Letter on Drugs and Therapeutics • June 16, 2008; (Issue 1288)
Etravirine (Intelence - Tibotec), a new non-nucleoside reverse transcriptase inhibitor (NNRTI), has received fast-track FDA approval for use in combination therapy in treatment-experienced adults who have HIV-1...
Etravirine (Intelence - Tibotec), a new non-nucleoside reverse transcriptase inhibitor (NNRTI), has received fast-track FDA approval for use in combination therapy in treatment-experienced adults who have HIV-1 infection resistant to an NNRTI and other antiretroviral agents.
Which Statin?
The Medical Letter on Drugs and Therapeutics • April 21, 2008; (Issue 1284)
Advertisements for atorvastatin (Lipitor), the market leader facing generic competition, have been in the news recently in the US. Lovastatin, pravastatin and simvastatin are all available generically at a much...
Advertisements for atorvastatin (Lipitor), the market leader facing generic competition, have been in the news recently in the US. Lovastatin, pravastatin and simvastatin are all available generically at a much lower retail price or lower co-pay than atorvastatin.
Antifungal Drugs
The Medical Letter on Drugs and Therapeutics • January 1, 2008; (Issue 65)
The drugs of choice for treatment of some fungal infections are listed in the tables. Some of the indications and dosages recommended here have not been approved by the FDA. Other guidelines are available from...
The drugs of choice for treatment of some fungal infections are listed in the tables. Some of the indications and dosages recommended here have not been approved by the FDA. Other guidelines are available from the Infectious Diseases Society of America (www.idsociety.org).
Drugs for HIV Infection
The Medical Letter on Drugs and Therapeutics • October 1, 2006; (Issue 50)
The approval of new drugs and continuing concerns about drug toxicity and resistance have prompted new antiretroviral treatment guidelines. Resistance testing is not recommended before starting antiretroviral...
The approval of new drugs and continuing concerns about drug toxicity and resistance have prompted new antiretroviral treatment guidelines. Resistance testing is not recommended before starting antiretroviral therapy. HIV infection is treated with combinations of antiretroviral drugs while monitoring the patient's HIV RNA levels ("viral load") and CD4 cell count. Increases in viral load while on therapy may indicate development of drug resistance requiring further testing and a change in treatment regimen.
Darunavir (Prezista) for HIV Infection
The Medical Letter on Drugs and Therapeutics • September 11, 2006; (Issue 1243)
Darunavir (Prezista - Tibotec), a new protease inhibitor, has received accelerated approval from the FDA for use in combination therapy of human-immunodeficiency virus (HIV) infection in previously treated...
Darunavir (Prezista - Tibotec), a new protease inhibitor, has received accelerated approval from the FDA for use in combination therapy of human-immunodeficiency virus (HIV) infection in previously treated adults. It is coadministered with low-dose ritonavir (Norvir), which increases its bioavailability.
Tipranavir (Aptivus) for HIV
The Medical Letter on Drugs and Therapeutics • October 10, 2005; (Issue 1219)
Tipranavir (Aptivus - Boehringer Ingelheim), a new protease inhibitor, has received accelerated approval from the FDA. It must be given with ritonavir (Norvir). The combination is indicated for use with other...
Tipranavir (Aptivus - Boehringer Ingelheim), a new protease inhibitor, has received accelerated approval from the FDA. It must be given with ritonavir (Norvir). The combination is indicated for use with other antiretrovirals to treat HIV infection in highly treatment-experienced adults who have ongoing viral replication or in those with HIV strains known to be resistant to multiple protease inhibitors.
CYP3A and Drug Interactions
The Medical Letter on Drugs and Therapeutics • July 4, 2005; (Issue 1212)
Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in the...
Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in the metabolism of more than 50 percent of currently prescribed drugs.2 CYP3A4, which is more abundantly expressed than CYP3A5, accounts for most CYP3A activity in vivo.
Safety of Aggressive Statin Therapy
The Medical Letter on Drugs and Therapeutics • November 22, 2004; (Issue 1196)
New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from...
New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from <100 mg/dL to <70 mg/dL for patients at very high risk for coronary heart disease and from 130 mg/dL to <100 mg/dL for those at moderately high risk. A likely consequence of these recommendations is increased use of statins and use of higher doses with a concomitant increase in adverse effects.
Drugs for HIV
The Medical Letter on Drugs and Therapeutics • January 1, 2004; (Issue 17)
New drug approvals as well as continuing concerns about drug toxicity and the development of resistance have prompted new antiretroviral treatment guidelines (Panel on Clinical Practices for Treatment of HIV...
New drug approvals as well as continuing concerns about drug toxicity and the development of resistance have prompted new antiretroviral treatment guidelines (Panel on Clinical Practices for Treatment of HIV Infection, November 10, 2003, www.aidsinfo.nih.gov).
Atazanavir (Reyataz) and Emtricitabine (Emtriva) for HIV Infection
The Medical Letter on Drugs and Therapeutics • November 10, 2003; (Issue 1169)
Atazanavir (Reyataz - Bristol-Myers Squibb), a new protease inhibitor (PI), and emtricitabine (Emtriva - Gilead), a nucleoside analogue reverse transcriptase inhibitor (NRTI) chemically similar to lamivudine,...
Atazanavir (Reyataz - Bristol-Myers Squibb), a new protease inhibitor (PI), and emtricitabine (Emtriva - Gilead), a nucleoside analogue reverse transcriptase inhibitor (NRTI) chemically similar to lamivudine, have been approved by the FDA for treatment of HIV-1 infection. Both are taken once daily, unlike most anti-HIV drugs.
Drug Interactions
The Medical Letter on Drugs and Therapeutics • June 8, 2003; (Issue 1158)
Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug...
Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.
Buprenorphine: An alternative to Methadone
The Medical Letter on Drugs and Therapeutics • February 17, 2003; (Issue 1150)
The FDA has approved the marketing of buprenorphine in sublingual tablets (Reckitt Benckiser) both alone (Subutex) and with naloxone (Suboxone) for treatment of opioid dependence. Previously available only...
The FDA has approved the marketing of buprenorphine in sublingual tablets (Reckitt Benckiser) both alone (Subutex) and with naloxone (Suboxone) for treatment of opioid dependence. Previously available only for parenteral use in treatment of pain (Buprenex, and others), it offers an alternative to methadone (Dolophine, and others), which is now often abused (New York Times, February 9, 2003; page 1). As a schedule III narcotic, buprenorphine will be subject to fewer prescribing restrictions than a schedule II drug such as methadone (MJ Kreek and FJ Vocci, J Subst Abuse Treat 2002; 23:93).w1150a
Drugs for HIV
The Medical Letter on Drugs and Therapeutics • November 26, 2001; (Issue 1119)
Since the last Medical Letter article on this subject, continuing concerns about drug toxicity and development of resistance have prompted new antiretroviral treatment guidelines. The dosage and cost of drugs...
Since the last Medical Letter article on this subject, continuing concerns about drug toxicity and development of resistance have prompted new antiretroviral treatment guidelines. The dosage and cost of drugs for HIV infection are listed in the table in this article.
Drugs for HIV Infection
The Medical Letter on Drugs and Therapeutics • January 10, 2000; (Issue 1069)
Highly active anti-retroviral therapy (HAART) combining three or four drugs has become the standard of care for treatment of human immunodeficiency virus (HIV)...
Highly active anti-retroviral therapy (HAART) combining three or four drugs has become the standard of care for treatment of human immunodeficiency virus (HIV) infection
Amprenavir: A New HIV Protease Inhibitor
The Medical Letter on Drugs and Therapeutics • July 16, 1999; (Issue 1057)
Amprenavir is the fifth protease inhibitor to become available for treatment of HIV infection. It was approved by the FDA for use with other drugs in the treatment of HIV-infected adults and children at least...
Amprenavir is the fifth protease inhibitor to become available for treatment of HIV infection. It was approved by the FDA for use with other drugs in the treatment of HIV-infected adults and children at least four years old.
Drug Interactions
The Medical Letter on Drugs and Therapeutics • July 2, 1999; (Issue 1056)
Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new...
Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new drugs.
Three New Drugs for HIV Infection
The Medical Letter on Drugs and Therapeutics • December 4, 1998; (Issue 1041)
Combination antiretroviral therapy including protease inhibitors has dramatically changed the treatment of HIV infection and the prognosis of those affected (Medical Letter Handbook of Antimicrobial Therapy,...
Combination antiretroviral therapy including protease inhibitors has dramatically changed the treatment of HIV infection and the prognosis of those affected (Medical Letter Handbook of Antimicrobial Therapy, 1998, page 122). Due to limitations and failures with these drugs in many patients, however, three new drugs, none of them protease inhibitors, have rapidly come into wide use in clinical trials or 'expanded access' programs. They are abacavir (Ziagen - Glaxo Wellcome), adefovir (Preveon - Gilead) and efavirenz (Sustiva - DuPont). Efavirenz was recently approved for treatment of adults and children by the FDA. Abacavir has been recommended for approval by an FDA advisory committee.
Drugs for HIV Infection
The Medical Letter on Drugs and Therapeutics • December 5, 1997; (Issue 1015)
Recent studies have led to changes in the approach to treating human immunodeficiency virus (HIV) infection (CCJ Carpenter et al, JAMA, 277:1962, 1997). None of the drugs currently available to treat...
Recent studies have led to changes in the approach to treating human immunodeficiency virus (HIV) infection (CCJ Carpenter et al, JAMA, 277:1962, 1997). None of the drugs currently available to treat HIV-infected patients has been shown to eradicate the infection, but used in combination they can decrease viral replication, improve immunologic status, delay infectious complications and prolong life. The drug regimens recommended by Medical Letter consultants are listed in the table on page 114. Adult regimens and dosages may not be applicable to children (Guidelines for use of Antiretroviral Agents in Pediatric HIV Infection, HIV/AIDS Treatment Information Services, www.hivatis.org/glarvped.html). Some drugs interactions of anti-HIV drugs are listed on the table that begins on page 115.
More New Drugs for HIV and Associated Infections
The Medical Letter on Drugs and Therapeutics • February 14, 1997; (Issue 994)
Four new drugs have become available in the USA for HIV infection or its complications. Nevirapine (Viramune - Roxane), intravenous cidofovir (Vistide - Gilead), and amphotericin B oral suspension (Fungizone...
Four new drugs have become available in the USA for HIV infection or its complications. Nevirapine (Viramune - Roxane), intravenous cidofovir (Vistide - Gilead), and amphotericin B oral suspension (Fungizone Oral Suspension - Bristol-Myers Squibb) have been approved by the US Food and Drug Administration; nelfinavir (Viracept - Agouron) is currently available only through an "Expanded Access Program."
New Drugs for HIV Infection
The Medical Letter on Drugs and Therapeutics • April 12, 1996; (Issue 972)
The US Food and Drug Administration (FDA) has approved the marketing of five new drugs for treatment of HIV Infection. Stavudine (D4T; Zerit - Bristol-Myers Squibb) and lamivudine (3TC; Epivir - Glaxo...
The US Food and Drug Administration (FDA) has approved the marketing of five new drugs for treatment of HIV Infection. Stavudine (D4T; Zerit - Bristol-Myers Squibb) and lamivudine (3TC; Epivir - Glaxo Wellcome) are nucleoside analogs similar to zidovudine (AZT), didanosine (ddl) and zalcitabine (ddC). Saquinavir (Invirase - Roche), ritonavir (Norvir - Abbott) and indinavir (Crixivan - Merck) are protease inhibitors, a new class of anti-HIV drugs.
Drugs for AIDS and Associated Infections
The Medical Letter on Drugs and Therapeutics • October 13, 1995; (Issue 959)
Results of recently completed clinical trials have led to some changes in recommendation for treatment of human immunodeficiency virus (HIV) and other infections associated with...
Results of recently completed clinical trials have led to some changes in recommendation for treatment of human immunodeficiency virus (HIV) and other infections associated with AIDS.